Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease
The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome and is rapidly emerging as the leading cause of liver-related morbidity and mortality. Macrophages play an essential role in the development and progression of NAFLD. AREAS COVERED: In this review, we provide an update on recent studies of drugs, which directly or indirectly affect macrophages in NAFLD, and discuss the implication of macrophage biomarkers to monitor the disease stage and progression/regression. EXPERT OPINION: There is an unmet need for a better understanding of disease pathogenesis from hepatic fat accumulation to disease progression with inflammation and fibrosis. We expect that future research will uncover additional objects/pathways as treatment targets. We speculate that this will involve better characterization of the gut microbiome, damage-associated molecular patterns (DAMPS) or molecules and pathways involved in the development of DAMPS, and advanced molecular biology studies including single-cell sequencing of macrophage subpopulations. In addition, we speculate that studies focusing on pharmaceuticals that improve insulin resistance, diminish the metabolic syndrome, and reduce fibrosis will prevail.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“some studies suggest that Kupffer cells express GLP-1 receptors and could thus also respond to GLP-1 receptor agonists.47”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [47]
Citations
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0027 · Cited by 3,889
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · cited 1×
“some of them have a more progressive sub-phenotype with steatohepatitis and advanced liver fibrosis or cirrhosis, which is the major determinant of liver-related prognosis in NAFLD [2,3].”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“However, there was no significant between-group difference in the percentage of patients with an improvement in fibrosis stage [66].”
Background(2011) · Hepatogastroenterology · doi:10.5754/hge11589 · Cited by 1,756
Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations
MacParland, S. A., Liu, J. C., Ma, X.-Z., Innes, B. T., Bartczak, A. M., Gage, B. K., Manuel, J., Khuu, N., Echeverri, J., Linares, I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06318-7 · Cited by 1,552 · cited 1×
“studies of NAFLD, particularly in the setting of steatohepatitis [9,10].”
BackgroundLee, J. Y., Sohn, K. H., Rhee, S. H., & Hwang, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011695200 · Cited by 1,299
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“metabolites of these fatty acids cause liver injury [24].”
Background
Research works printed but not linked: 3
- Chen L, 2012, Hepato-gastroenterology, 59, 1208
- Ho MK, 1982, Journal of Immunology (Baltimore, MD: 1950), 128, 2281
- Bird TG, 2013, Science, 110, 6542
Cited by
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
MAFLD as part of systemic metabolic dysregulation
Zhao, J., Liu, L., Cao, Y., Gao, X., Targher, G., Byrne, C. D., Sun, D., & Zheng, M. (2024) · Hepatology International · doi:10.1007/s12072-024-10660-y · Cited by 73
“Thus, these findings highlight the notion that liver macrophages may be an important potential target for halting injury and progression in MAFLD [68].”
Macrophage Signaling Pathways in Health and Disease: From Bench to Bedside Applications
Chi, Y., Jiang, H., Yin, Y., Zhou, X., Shao, Y., Li, Y., & Rao, J. (2025) · MedComm · doi:10.1002/mco2.70256 · Cited by 62
Zhang, Y.-T. Y., Zhang, L., Zhao, Y., He, J., Zhang, Y., & Zhang, X. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01636-2 · Cited by 39
“…(ALT) assay kits (Jiancheng Biological Engineering Institute, Nanjing, Jiangsu, China), Sirius red biochemical reagent (Solarbio Life Science, Beijing, China) and Streptomycin-biotin peroxidase immuno-histochemical staining kits (Maixin Biological Technology, (Fuzhou, Fujian, China).”
Saldarriaga, Ó. A., Wanninger, T. G., Arroyave, E., Gosnell, J., Krishnan, S., Oneka, M. D., Bao, D., Millian, D. E., Kueht, M., Moghe, A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100958 · Cited by 28
Metadata
- Authors
- Laursen, T. L., Mellemkjær, A., Møller, H. J., Grønbæk, H., & Kazankov, K.
- Affiliations
- Regional Hospital Randers (DK)
- Aarhus University Hospital (DK)
- Corresponding author
- Grønbæk, Henning
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2022-08-03
- Volume
- 26
- Issue
- 8
- Pages
- 697-705
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W4303198237
- Cited by
- 12
- References
- 74
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 4
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Therapeutic Targets (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Steno Diabetes Center Aarhus
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, hepatic macrophages, liver fibrosis, liver inflammation, metabolic syndrome, insulin resistance, gut microbiota, damage-associated molecular patterns, macrophage heterogeneity, single-cell sequencing
- MeSH terms
- Pharmaceutical Preparations, Fibrosis, Humans, Liver, Macrophages, Disease Progression, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease. https://app.cochat.ai/papers/10.1080/14728222.2022.2132145
- The paper
- Laursen, T. L., Mellemkjær, A., Møller, H. J., Grønbæk, H., & Kazankov, K. (2022). Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2022.2132145
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.